Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Lupin is currently trading at Rs. 2048.20, up by 24.90 points or 1.23% from its previous closing of Rs. 2023.30 on the BSE.
The scrip opened at Rs. 2033.00 and has touched a high and low of Rs. 2051.00 and Rs. 2025.75 respectively. So far 712798 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1307.10 on 16-Oct-2014.
Last one week high and low of the scrip stood at Rs. 2103.00 and Rs. 2003.00 respectively. The current market cap of the company is Rs. 92055.70 crore.
The promoters holding in the company stood at 46.56% while Institutions and Non-Institutions held 43.45% and 9.99% respectively.
Pharma major Lupin and Boehringer Ingelheim have entered into a joint strategic alliance for co-marketing linagliptin, a novel Dipeptidylpeptidase-4 (DPP-4) inhibitor in India. Boehringer Ingelheim, one of the fastest growing multinational pharmaceutical company in India has a strong presence in the DPP-4 Inhibitors market in India which is growing at 27%.
According to the agreement, the company will market and sell linagliptin under a separate brand name Ondero (monotherapy) and Ondero Met (fixed-dose combination with metformin) which will be promoted by the company’s 400 strong dedicated Diabetes specialty field force. Boehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combination with metformin) through their existing sales force and network.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1515.00 |
| Dr. Reddys Lab | 6080.25 |
| Cipla | 1565.50 |
| Zydus Lifesciences | 1110.95 |
| Lupin | 1601.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
